What is Leucid Bio?
Leucid Bio is a pioneering cell therapy company headquartered in London, United Kingdom. The company is dedicated to developing a pipeline of novel cell therapies, leveraging its proprietary engine to create treatments for patients with solid tumors who currently have no viable treatment options. A key focus for Leucid Bio is the advancement of chimeric antigen receptor T cell (CAR T) therapies, a cutting-edge approach in oncology.
How much funding has Leucid Bio raised?
Leucid Bio has raised a total of $16M across 1 funding round:
Series A
$16M
Series A (2021): $16M with participation from Epidarex Capital, Future Fund, 2Invest, and Vulpes Investment Management
Key Investors in Leucid Bio
Epidarex Capital
Epidarex Capital is a transatlantic venture capital firm that focuses on building breakthrough life science companies in emerging hubs. They act as trusted partners to founders and co-investors, utilizing their deep scientific and industry networks to create exceptional value and shared success.
Future Fund
Future Fund, established in 2006, invests for the benefit of future generations of Australians by helping to meet unfunded public sector superannuation liabilities and ease growing pressure on government finances. It is headquartered in Australia.
Vulpes Investment Management
Vulpes Investment Management is an opportunistic alternative investment manager focused on long-term value creation and aligning incentives with investors. They aim to create sustainable capital appreciation through co-investment opportunities and a patient investment approach that prioritizes benefits beyond financial returns.
What's next for Leucid Bio?
The recent major strategic investment signals a pivotal moment for Leucid Bio, likely enabling the company to accelerate its research and development efforts, expand its clinical trial pipeline, and potentially scale its manufacturing capabilities. This significant backing from enterprise-level investors suggests strong confidence in Leucid Bio's technology and its potential to address unmet needs in cancer treatment, positioning the company for substantial growth and future milestones in the competitive cell therapy landscape.
See full Leucid Bio company page
